Rethinking Prophylactic Laser Peripheral Iridotomy in Primary Angle-Closure Suspects: A Review.

Autor:	Filippopoulos T; Athens Vision Eye Institute, Athens, Greece. Electronic address: tfilippopoulos@gmail.com., Danias J; Department of Ophthalmology at SUNY Downstate Health Sciences University, New York, New York., Karmiris E; Hellenic Air Force General Hospital, Attika, Greece., Mégevand GS; Clinical Eye Research Centre, A. Rothschild Foundation, Geneva, Switzerland., Rhee DJ; University Hospitals, Case Western Reserve University, Cleveland, Ohio., Gazzard G; NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; Institute of Ophthalmology, University College London, United Kingdom., Topouzis F; First Department of Ophthalmology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece., Xu B; Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.
Jazyk:	angličtina
Zdroj:	Ophthalmology. Glaucoma [Ophthalmol Glaucoma] 2023 Nov-Dec; Vol. 6 (6), pp. 657-667. Date of Electronic Publication: 2023 Jun 13.
DOI:	10.1016/j.ogla.2023.06.004
Abstrakt:	Purpose: To examine the generalizability, discuss limitations, and critically appraise recommendations on the management of primary angle-closure suspects (PACSs) that emerged as a result of recent randomized clinical trials challenging the widely accepted clinical practice of offering laser peripheral iridotomy (LPI) to PACS patients. To synthetize findings from these and other studies. Design: Narrative review. Subjects: Patients classified as PACS. Methods: The Zhongshan Angle-Closure Prevention (ZAP)-Trial and the Singapore Asymptomatic Narrow Angle Laser Iridotomy Study (ANA-LIS) along with accompanying publications were reviewed. Epidemiologic studies reporting on the prevalence of primary angle-closure glaucoma and other precursor forms of the disease were also analyzed along with publications reporting on the natural course of the disease or studies reporting on outcomes after prophylactic LPI. Main Outcome Measures: Incidence of progression to more severe forms of angle closure. Results: Patients recruited in recent randomized clinical trials are asymptomatic, do not have cataracts, may be younger, and have, on average, deeper anterior chambers depth compared with patients treated with LPI in clinics. Conclusions: The ZAP-Trial and ANA-LIS clearly represent the best available data on PACS management, additional parameters however may need to be considered when physicians face patients in clinic. PACS patients encountered at tertiary referral centers may represent more advanced cases with respect to ocular biometric parameters and may be at higher risk for disease progression compared with those recruited through population-based screening. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. (Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu